Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial
PaperCitations, authors & open-access status
Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 461 citations, 2021 year and closed oa status.
461
Citations
2021
Year
closed
OA Status